Correction: Overall survival of palbociclib plus endocrine therapy in Japanese patients with HR+/HER2− advanced breast cancer in the first-or second-line setting: a multicenter observational study (P-BRIDGE study)

Breast Cancer 2026 Open access

Read full text
Authors: Shigenori E. Nagai, Masaya Hattori, Tetsuhiro Yoshinami, Hiroko Masuda, Takuho Okamura, Kenichi Watanabe, Takahiro Nakayama, Michiko Tsuneizumi, Daisuke Takabatake, Michiko Harao, Hiroshi Yoshino, Natsuko Mori
+11 more Hiroyuki Yasojima, Chiya Oshiro, Madoka Iwase, Miki Yamaguchi, Takafumi Sangai, Shinsuke Sasada, Takanori Ishida, Manabu Futamura, Yasuaki Muramatsu, Nobuyoshi Kosaka, Norikazu Masuda
DOI: 10.1007/s12282-025-01787-3
Cited by: 1

Abstract

Correction: Overall survival of palbociclib plus endocrine therapy in Japanese patients with HR+/HER2- advanced breast cancer in the first-or second-line setting: a multicenter observational study (P-BRIDGE study)

Fields of Study & Subjects

Advanced Breast Cancer Therapies HER2/EGFR in Cancer Research Breast Cancer Treatment Studies

Publication details

Journal / source
Breast Cancer
Publisher
Springer Science and Business Media LLC
Volume
33
Issue
2
Pages
559–568
Publication date
27 January 2026
Language
EN